Compare Amphastar Pharmaceuticals Inc (AMPH) vs Brown-Forman Corporation Class B (BF.B) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Brown-Forman Corporation Class B — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Brown-Forman Corporation Class B trades at $26.27. The key difference: Brown-Forman Corporation Class B is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | BF.B | |
|---|---|---|
Market Cap | $826.08M | — |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $31.26 |
52-Week Low | $16.87 | $22.80 |
Enterprise Value | $1.22B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
BF.B trades at $26.17, up 3.77% today, with a bearish technical signal from moving averages but neutral oscillators. Recent earnings show three beats out of four quarters, with Q2 2024 EPS of $0.48 exceeding the $0.46 estimate. Analyst consensus is mixed, with 25% buy, 50% hold, and 25% sell ratings, reflecting cautious optimism amid weak valuation ratio data.
The stock faces headwinds from bearish technical trends and incomplete fundamental metrics, but consistent earnings beats provide a positive catalyst. Risks include market volatility and lack of recent news, while institutional sentiment remains divided. Upside depends on future financial disclosures confirming profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Brown-Forman Corporation Class B
Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.
Read more on BF.B →
